Cheapest Swap Mounjaro to Wegovy UK - From £69

How to Swap Mounjaro to Wegovy Safely: UK Clinical Guidance

Many patients choose to swap Mounjaro to Wegovy for reasons including cost, availability, or clinical response. Both tirzepatide (Mounjaro) and semaglutide (Wegovy) are GLP-1 receptor agonists licensed by the MHRA for chronic weight management, but transitioning between them requires careful dose conversion and clinical oversight from a UK prescriber to maintain efficacy and minimise side effects.

Why Patients Swap Mounjaro to Wegovy in the UK

The decision to swap Mounjaro to Wegovy typically stems from three primary factors: cost considerations, medication availability, or individual treatment response. Wegovy (semaglutide) is priced from £89 at Cured Pharmacy compared to Mounjaro's £145 starting price, representing a significant monthly saving for long-term weight management programmes [1]. Both medications demonstrate robust efficacy in clinical trials, with STEP trials showing semaglutide achieving average weight loss of 15-17% body weight, whilst SURPASS trials demonstrated tirzepatide achieving 15-22% depending on dose [2].

Some patients experience better tolerability with semaglutide's single GLP-1 mechanism compared to tirzepatide's dual GIP/GLP-1 action, particularly regarding gastrointestinal side effects. Supply chain considerations also influence switching decisions, as periodic shortages of either medication in the UK market may necessitate temporary or permanent transitions. Our superintendent pharmacist Tarun Kumar regularly advises patients on these transitions, ensuring continuity of care whilst optimising both clinical outcomes and treatment affordability subject to prescriber approval.

Clinical Protocol to Swap Mounjaro to Wegovy Doses

When you swap Mounjaro to Wegovy, direct dose equivalence is not straightforward as tirzepatide and semaglutide have different receptor mechanisms and potency profiles. Clinical guidance suggests matching doses based on treatment phase rather than milligram-for-milligram conversion [3]. Patients established on Mounjaro 2.5mg (initial dose) typically transition to Wegovy's standard 0.25mg starting dose, following the manufacturer's escalation schedule over 16-20 weeks to the maintenance dose of 2.4mg weekly.

For patients on higher Mounjaro doses (5mg, 7.5mg, 10mg, 12.5mg, or 15mg), UK prescribers generally recommend starting Wegovy at 0.5mg or 1mg weekly rather than the lowest 0.25mg dose, then escalating to 2.4mg based on tolerability. This approach maintains therapeutic GLP-1 activity whilst allowing the body to adjust to semaglutide's pharmacokinetic profile, which has a longer half-life (approximately 7 days) compared to tirzepatide (approximately 5 days) [4]. All dose transitions require assessment by a UK-registered prescriber through our clinical consultation process.

Timing Your Transition Between Injections

The optimal timing to swap Mounjaro to Wegovy involves a washout consideration, though most UK prescribers recommend a seamless transition without a medication-free gap to prevent weight regain. Administer your first Wegovy injection on the day your next Mounjaro dose would have been due, maintaining the once-weekly injection schedule. Both medications are administered subcutaneously in the abdomen, thigh, or upper arm, and you may continue using the same injection sites. Monitor for any changes in appetite suppression or side effects during the first 4-6 weeks, reporting concerns to your prescriber for potential dose adjustment.

Cost Comparison: Swap Mounjaro to Wegovy for Savings

Financial considerations drive many patients to swap Mounjaro to Wegovy, particularly for long-term weight management extending 12-24 months or longer. At Cured Pharmacy, Wegovy starts from £89 per month compared to Mounjaro's £145 starting price. On maintenance doses (Wegovy 2.4mg £199, Mounjaro 15mg £287) the potential annual saving is £1,056. New patients receive an additional £20 off their first order using discount code Weightlossnew, reducing the initial Wegovy cost to £69 subject to clinical approval.

Whilst both treatments require ongoing investment, the lower Wegovy pricing makes sustained weight loss more accessible for UK patients without compromising clinical efficacy. The STEP 1 trial demonstrated that semaglutide 2.4mg maintained weight loss over 68 weeks, with participants losing an average of 14.9% body weight compared to 2.4% with placebo [5]. This evidence supports the cost-effectiveness of switching to the more affordable option when clinically appropriate, as long-term adherence is critical for preventing weight regain.

Expected Outcomes When You Swap Mounjaro to Wegovy

Patients who swap Mounjaro to Wegovy typically maintain their weight loss trajectory, though individual responses vary based on dose equivalence, lifestyle factors, and metabolic adaptation. Clinical experience suggests that patients established on Mounjaro 5mg or higher who transition to Wegovy 2.4mg (the maximum licensed dose) may experience slightly different appetite suppression patterns during the initial 4-8 weeks as semaglutide reaches steady-state plasma concentrations [6].

Some patients report enhanced tolerability with Wegovy due to semaglutide's selective GLP-1 receptor agonism, whilst others prefer tirzepatide's dual mechanism. Weight maintenance or continued gradual loss is the expected outcome when the transition is managed appropriately with dose titration, dietary consistency, and physical activity. Our clinical team monitors all patients through follow-up consultations, adjusting treatment plans to optimise outcomes whilst managing any emerging side effects such as nausea, constipation, or injection site reactions.

Managing Side Effects During the Transition

Gastrointestinal side effects may temporarily increase or decrease when you swap Mounjaro to Wegovy, depending on your previous tolerance and the transition dose selected. Common effects include nausea, diarrhoea, constipation, and reduced appetite, typically most pronounced during dose escalation phases. Starting Wegovy at a lower dose than your final Mounjaro dose allows gradual adaptation, minimising discomfort. Eating smaller, more frequent meals, avoiding high-fat foods, and maintaining hydration support tolerability. Persistent or severe side effects warrant prescriber consultation for potential dose modification or additional symptomatic management strategies.

How to Swap Mounjaro to Wegovy at Cured Pharmacy

Initiating your transition to swap Mounjaro to Wegovy at Cured Pharmacy begins with our streamlined online consultation, completed in under 3 minutes. Our UK-registered prescribers review your current Mounjaro dose, treatment duration, weight loss progress, medical history, and any side effects experienced to determine the appropriate starting Wegovy dose. All consultations are conducted by GMC-registered clinicians, ensuring safe, evidence-based prescribing aligned with MHRA and NICE guidance [7].

Once approved, your Wegovy prescription is dispensed by our GPhC-registered pharmacy (registration 9012511) and dispatched in 100% discreet packaging with next-day delivery options available across the UK. Transparent pricing is displayed before consultation, with no hidden fees. Ongoing support includes follow-up consultations to monitor progress, adjust doses, and address any clinical concerns. New patients Save £20 using code Weightlossnew at checkout, making the initial transition more affordable whilst maintaining the highest standards of pharmaceutical care under superintendent pharmacist Tarun Kumar's oversight.

Swap Mounjaro to Wegovy: Long-Term Weight Management Strategy

Successfully maintaining weight loss after you swap Mounjaro to Wegovy requires integrating medication with sustainable lifestyle modifications. Both tirzepatide and semaglutide work by reducing appetite, slowing gastric emptying, and improving glycaemic control, but these mechanisms support rather than replace healthy eating patterns and regular physical activity [8]. UK clinical guidelines recommend combining GLP-1 therapy with a reduced-calorie diet (typically 500-1000 kcal daily deficit) and at least 150 minutes of moderate-intensity exercise weekly for optimal outcomes.

Long-term data from the STEP trials indicate that continued semaglutide treatment maintains weight loss, whilst discontinuation often leads to weight regain, highlighting the chronic nature of obesity management. Patients who swap Mounjaro to Wegovy should view this as a long-term commitment, with regular prescriber reviews every 3-6 months to assess efficacy, tolerability, and the ongoing appropriateness of pharmacotherapy. Cured Pharmacy supports this journey with accessible pricing, reliable UK supply, and continuous clinical oversight to help patients achieve and sustain meaningful weight reduction.

When Switching May Not Be Appropriate

Certain clinical scenarios may make it inadvisable to swap Mounjaro to Wegovy without careful prescriber evaluation. Patients who have achieved exceptional results on higher Mounjaro doses (12.5mg or 15mg) may not achieve equivalent outcomes on Wegovy's maximum 2.4mg dose due to tirzepatide's dual-agonist potency. Those with a history of severe gastrointestinal side effects on semaglutide products (including Ozempic) may not tolerate Wegovy well. Additionally, patients with specific contraindications to semaglutide, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, should not transition. Always disclose complete medical history during consultation to ensure safe, appropriate prescribing.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
3. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet, 397(10278), 971-984. [accessed 15 August 2026]
4. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. [accessed 15 August 2026]
5. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
6. Smits, M. M., & Van Raalte, D. H. (2021). Safety of semaglutide. Frontiers in Endocrinology, 12, 645563. [accessed 15 August 2026]
7. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. [accessed 15 August 2026]
8. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 15 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.